KCM
TEVA icon

Kingdon Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Kingdon Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-200,000
Closed -$3.79M – 135
2017
Q4 		$3.79M Buy
+200,000
New +$3.01M 0.24% 90

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Kingdon Capital Management's TEVA Position: Q2 2015 in Review

Kingdon Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 40,000 shares — an estimated $2.49M sold.

Kingdon Capital Management first reported a position in TEVA in Q2 2013 and held it in 3 quarters. The position peaked at $10.5M in Q2 2014. 819 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

  • Kingdon Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Kingdon Capital Management sold 40,000 Teva Pharmaceuticals shares in Q2 2015, an estimated $2.49M.
  • Kingdon Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Kingdon Capital Management's Teva Pharmaceuticals position peaked at $10.5M in Q2 2014.
  • 819 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on Kingdon Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.